TW200716096A - Combination drug - Google Patents

Combination drug

Info

Publication number
TW200716096A
TW200716096A TW095114109A TW95114109A TW200716096A TW 200716096 A TW200716096 A TW 200716096A TW 095114109 A TW095114109 A TW 095114109A TW 95114109 A TW95114109 A TW 95114109A TW 200716096 A TW200716096 A TW 200716096A
Authority
TW
Taiwan
Prior art keywords
combination drug
combination
supeirior
dpp
prophylactic
Prior art date
Application number
TW095114109A
Other languages
English (en)
Inventor
Noriyuki Miyata
Shinichiro Kumeda
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of TW200716096A publication Critical patent/TW200716096A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
TW095114109A 2005-04-22 2006-04-20 Combination drug TW200716096A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005124495A JP2008115080A (ja) 2005-04-22 2005-04-22 併用医薬

Publications (1)

Publication Number Publication Date
TW200716096A true TW200716096A (en) 2007-05-01

Family

ID=36636547

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095114109A TW200716096A (en) 2005-04-22 2006-04-20 Combination drug

Country Status (3)

Country Link
JP (1) JP2008115080A (zh)
TW (1) TW200716096A (zh)
WO (1) WO2006115289A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0616195A2 (pt) 2005-09-20 2011-06-14 Novartis Ag uso de um inibidor de dpp-iv para reduzir eventos hipoglicÊmicos
CA2681092A1 (en) * 2007-03-15 2008-09-18 Nectid, Inc. Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
WO2010074271A1 (ja) * 2008-12-26 2010-07-01 武田薬品工業株式会社 糖尿病治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1741447E (pt) * 2000-01-21 2013-12-11 Novartis Ag Combinações que compreendem o inibidor da dipeptidilpeptidase-iv
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2003057144A2 (en) * 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
WO2005117861A1 (en) * 2004-06-04 2005-12-15 Novartis Ag Use of organic compounds

Also Published As

Publication number Publication date
JP2008115080A (ja) 2008-05-22
WO2006115289A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
IL249715B (en) N-butyl-deoxynojirimycin for use as a drug for the treatment of Pompe disease in combination with an enzyme replacement therapy agent
WO2011012746A3 (es) Compuestos inhibidores de apaf-1
NZ619520A (en) Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
IL246402A (en) A therapeutic component for treating obesity, diabetes and impaired glucose tolerance
GEP20135838B (en) Dipeptidyl peptidase inhibitors usage at diabetes treatment
AP2320A (en) Proline derivatives and their use as dipeptidyl peptidase IV inhibitors.
CR9220A (es) Terapia combinatoria para el tratamiento de la diabetes y de condiciones relacionadas con la misma o para el tratamiento de condiciones mejoradas aumentando un nivel de glp-1 en sangre.
AU2008317057A8 (en) Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
WO2006053043A3 (en) Methods of treating diabetes mellitus
IL196869A0 (en) A pharmaceutical composition containing a hexahydrophenanthridin-2-ol derivative in combination with another active ingredient for treatment of diabetes mellitus
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
WO2005009398A3 (en) Tetracyclic benzamide derivatives and methods of use thereof
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
PL2275108T3 (pl) Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej
EP2015800A4 (en) MEDICAL INJECTOR WITH FRONT LOADING AND CORRESPONDING SYRINGES
SG160415A1 (en) Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2007106884A3 (en) Methods of treating muscular wasting diseases using nf-kb activation inhibitors
MX2009011900A (es) Curacion de herida diabetica.
BRPI0908168A2 (pt) composto, medicamento, inibidor de dipeptidil peptidase-iv, agente terapêutico para diabetes, e, método de tratamento de diabetes
TW200716096A (en) Combination drug
PH12014501646A1 (en) Substituted phenylazole derivative
HK1160031A1 (zh) 包含抑制二肽基肽酶- 活性的化合物以及其他抗糖尿病劑或抗肥胖劑作為活性成分的、用於預防和治療糖尿病或肥胖症的藥物組合物
IL191208A (en) Use of phenofibrate or its derivative for the preparation of a drug for the treatment of diabetic retinopathy
GB0313386D0 (en) Treatment of disease